share_log

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $42

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $42

派珀·桑德勒維持對Supernus Pharmicals的增持,將目標股價下調至42美元
Benzinga ·  2023/10/25 15:38

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and lowers the price target from $43 to $42.

派珀·桑德勒分析師David·安塞勒姆維持對納斯達克(Supernus PharmPharmticals)的增持,並將目標價從43美元下調至42美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論